Severe multi-resistant pemphigus vulgaris: Prolonged remission with a single cycle of Rituximab;Pênfigo vulgar grave multirresistente: Controle prolongado com um único ciclo de Rituximabe

Anais Brasileiros de Dermatologia

Volumn 88, Issue 4, 2013, Pages 639-642

  Corral, Isabela Soubhia ^a   De Freitas, Thais Helena Proença ^b   De Aquino, Renata Telles Rudge ^a   Koller, Daniella Abbruzzini S ^a   Ruffolo Magliari, Maria Elisa ^a   Muller, Helena ^a  

^a Santa Casa de Misericordia de Sao Paulo   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Desmogleins; Drug resistance; Pemphigus; Treatment failure

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; SULFONE;

ADULT; ARTICLE; BLISTER; CASE REPORT; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SUBSTITUTION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPOSI VARICELLIFORM ERUPTION; MALE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; ODYNOPHAGIA; PAIN; PEMPHIGUS VULGARIS; RELAPSE; SECONDARY INFECTION; SKIN BIOPSY; THROMBOCYTOPENIA; VESICULAR RASH;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG RESISTANCE, MULTIPLE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; MALE; PEMPHIGUS; PREDNISONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884789382     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20131990     Document Type: Article

References (10)

1. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008; 6:366-373.
2. Goebeler M, Herzog S, Bröcker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003;149:899-901.
3. Daniel BS, Murrell D F, Joly P. Rituximab and its use in autoimmune bullous disorders. Dermatol Clin. 2011;29:571-575.
4. Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int. 2008;28:205-215.
5. Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128:2859-2869.
6. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of Severe Pemphigus with Rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 2007;143:1033-1038.
7. Matsukura S, Knowles SR, Walsh S, Shear NH. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Arch Dermatol. 2012;148:734-739.
8. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545-552.
9. Diaz LA. Rituximab and pemphigus - a therapeutic advance. N Engl J Med. 2007;357:545-552.
10. Hertl M, Eming R, Borradori L. Rituximab (anti-CD20 monoclonal antibody)--ulti-mate or first choice in pemphigus? Dermatology. 2007;214: 275-277.